Lead Product(s) : ALKS 2680
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkermes Announces Initiation of Phase 2 Evaluating ALKS 2680 for Idiopathic Hypersomnia
Details : ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for idiopathic hypersomnia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2025
Lead Product(s) : ALKS 2680
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALKS2680
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 10, 2025
Lead Product(s) : ALKS2680
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAK-861
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Takeda Plans to Rapidly Initiate Global Phase 3 Trials of TAK-861 for Narcolepsy in 2024
Details : TAK-861 is an oral orexin agonist which is being evaluated in phase 2/3 clinical trials for the treatment of patients with Narcolepsy Type 1 & Type 2.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2024
Lead Product(s) : TAK-861
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IHL-42X
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2023
Lead Product(s) : IHL-42X
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAK-861
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : TAK-861
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acetazolamide,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 20% of participants experienced a reduction in AHI of greater than 80% relative to baseline during at least one treatment period of one dose strength of IHL-42X and, average of low, mid, and high-dose IHL-42X reduced AHI in trial participants by 44.4%, c...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : Acetazolamide,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cbti
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : University of Arizona | Proactive Life Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Enhanced CBTi for Older Adult Sleep and Cognition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 20, 2021
Lead Product(s) : Cbti
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : University of Arizona | Proactive Life Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Reboxetine Mesylate,Oxybutynin
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2021
Lead Product(s) : Reboxetine Mesylate,Oxybutynin
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AD128
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Apnimed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of AD128 to Treat Obstructive Sleep Apnea
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2020
Lead Product(s) : AD128
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Apnimed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2019
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable